{"description":"Documents matching 'peptide' and published on or after 08/01/2026","count":5,"total_pages":1,"results":[{"title":"Government Owned Invention Available for License: Human Antibodies Targeting Beneficial Viral Peptide in Liver Cancer","type":"Notice","abstract":"The National Cancer Institute (NCI) seeks research co- development partners and/or licensees to develop a collection of anti- CE1 antibodies for liver cancer treatment.","document_number":"2026-16442","html_url":"https://www.federalregister.gov/documents/2026/08/12/2026-16442/government-owned-invention-available-for-license-human-antibodies-targeting-beneficial-viral-peptide","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-08-12/pdf/2026-16442.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-16442.pdf?1786452318","publication_date":"2026-08-12","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"excerpts":"for more effective treatments. \n \n Previously, NIH investigators identified a novel viral <span class=\"match\">peptide</span> antigen known as CE1. CE1 belongs to the rhinovirus and enterovirus families (NIH Ref: E-023-2024) producing a dominant humoral response associated with reduced incidence and mortality of HCC. Through phage display from a human single-chain fragment variable (scFv) phage library, NCI inventors isolated two human antibodies (B9 and B10) against the viral <span class=\"match\">peptide</span>, CE1. Human anti-CE1 B9 and B10 antibodies were constructed. These antibodies showed specific"},{"title":"Potency Assessment of Active Immunotherapy Products; Draft Guidance for Industry; Availability","type":"Notice","abstract":"The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft document titled \"Potency Assessment of Active Immunotherapy Products.\" The draft guidance document provides recommendations for developing assays to assess potency as a part of a potency assurance strategy for active immunotherapy products (ACTIMPs). When finalized, this guidance will describe the FDA's current thinking regarding design, validation, and evaluation of potency tests for ACTIMPs. This guidance is intended to supplement the December 2023 draft guidance for industry, when finalized, on \"Potency Assurance for Cellular and Gene Therapy Products\" with additional advice and considerations specifically for ACTIMPs, including peptide- and-protein based ACTIMPs that are not cellular or gene therapy products.","document_number":"2026-16960","html_url":"https://www.federalregister.gov/documents/2026/08/20/2026-16960/potency-assessment-of-active-immunotherapy-products-draft-guidance-for-industry-availability","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-08-20/pdf/2026-16960.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-16960.pdf?1787143517","publication_date":"2026-08-20","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"of potency tests for ACTIMPs. This guidance is intended to supplement the December 2023 draft guidance for industry, when finalized, on “Potency Assurance for Cellular and Gene Therapy Products” with additional advice and considerations specifically for ACTIMPs, including <span class=\"match\">peptide</span>- and-protein based ACTIMPs that are not cellular or gene therapy products. \n \n \n DATES: \n Submit either electronic or written comments on the draft guidance by November 18, 2026 to ensure that the Agency considers your comment on this draft guidance before it begins work"},{"title":"Draft NIH Biosafety Policy for Research Involving Biohazards","type":"Notice","abstract":"As the world's largest public funder of biomedical research, the National Institutes of Health (NIH) is committed to ensuring that gold-standard science is conducted under gold-standard biosafety conditions. To achieve this goal, NIH is proposing a new policy that modernizes and strengthens biosafety practices to ensure that oversight keeps pace with evolving risks. NIH is requesting public input on a new, comprehensive biosafety policy proposal that, when finalized, will replace the current NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules (https://osp.od.nih.gov/wp-content/ uploads/NIH_Guidelines.pdf).","document_number":"2026-18646","html_url":"https://www.federalregister.gov/documents/2026/09/14/2026-18646/draft-nih-biosafety-policy-for-research-involving-biohazards","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-09-14/pdf/2026-18646.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-18646.pdf?1789130712","publication_date":"2026-09-14","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"excerpts":"or organisms generated by synthetic biology in conjunction with artificial intelligence).\n \n \n Prions and self-aggregating proteins: \n Misfolded forms of proteins that can self-propagate and cause neurodegenerative disease in humans or animals.\n \n \n Toxin: \n A protein or <span class=\"match\">peptide</span> produced by living organisms that causes harm in humans.\n \n \n Wild type: \n Naturally occurring organisms, cells, or viruses without deliberately introduced genetic modifications.\n \n \n Zoonotic: \n An agent reasonably suspected of transmission from animals to humans with the"},{"title":"Modernizing Medical Standards for Non-Insulin Dependent Diabetes Mellitus Cases","type":"Proposed Rule","abstract":"FAA proposes to amend its regulations to allow applicants with non-insulin dependent diabetes mellitus to apply for airman medical certification that may be issued at the time of their medical examination instead of requiring Special Issuance review by FAA. This action would reduce the burden associated with the process of review for Authorization for Special Issuance while recognizing that modern medical advancements have significantly improved the manageability of certain forms of diabetes.","document_number":"2026-18162","html_url":"https://www.federalregister.gov/documents/2026/09/04/2026-18162/modernizing-medical-standards-for-non-insulin-dependent-diabetes-mellitus-cases","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-09-04/pdf/2026-18162.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-18162.pdf?1788439514","publication_date":"2026-09-04","agencies":[{"raw_name":"DEPARTMENT OF TRANSPORTATION","name":"Transportation Department","id":492,"url":"https://www.federalregister.gov/agencies/transportation-department","json_url":"https://www.federalregister.gov/api/v1/agencies/492","parent_id":null,"slug":"transportation-department"},{"raw_name":"Federal Aviation Administration","name":"Federal Aviation Administration","id":159,"url":"https://www.federalregister.gov/agencies/federal-aviation-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/159","parent_id":492,"slug":"federal-aviation-administration"}],"excerpts":"alone, which has become the cornerstone of modern diabetes management.\n 16 \n \n In addition, newer glucose-lowering agents have produced a paradigm shift in preventing cardiovascular and renal complications. Sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like <span class=\"match\">peptide</span>-1 (GLP-1) receptor agonists reduce mortality and major cardiovascular events compared to usual care.\n 17 \n \n SGLT2 inhibitors specifically reduce progression to chronic kidney disease, heart failure hospitalizations, and severe hypoglycemia, while GLP-1 receptor agonists"},{"title":"Medicare Program; Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals (IPPS) and the Long-Term Care Hospital Prospective Payment System and Policy Changes and Fiscal Year (FY) 2027 Rates; Requirements for Quality Programs; Other Policy Changes; and Adoption of Updated Versions of Certain Health Information Technology Standards","type":"Rule","abstract":"This final rule will revise the Medicare hospital inpatient prospective payment systems (IPPS) for operating and capital-related costs of acute care hospitals; make changes relating to Medicare graduate medical education (GME) for teaching hospitals; update the payment policies and the annual payment rates for the Medicare prospective payment system (PPS) for inpatient hospital services provided by long-term care hospitals (LTCHs); update and make changes to requirements for certain quality programs; and make other policy- related changes. ONC also adopts certain health information technology (health IT) standards and specifications on behalf of HHS.","document_number":"2026-15833","html_url":"https://www.federalregister.gov/documents/2026/08/04/2026-15833/medicare-program-hospital-inpatient-prospective-payment-systems-for-acute-care-hospitals-ipps-and","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-08-04/pdf/2026-15833.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-15833.pdf?1785528912","publication_date":"2026-08-04","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Centers for Medicare & Medicaid Services","name":"Centers for Medicare & Medicaid Services","id":45,"url":"https://www.federalregister.gov/agencies/centers-for-medicare-medicaid-services","json_url":"https://www.federalregister.gov/api/v1/agencies/45","parent_id":221,"slug":"centers-for-medicare-medicaid-services"},{"raw_name":"Office of the Secretary"}],"excerpts":"defibrillator lead into right ventricle, percutaneous approach, new technology group 11).\n \n \n 12. PearlMatrix\n TM \n P-15 <span class=\"match\">Peptide</span> Enhanced Bone Graft\n \n \n Cerapedics, Inc. submitted a FY 2027 application for new technology add-on payments for PearlMatrix\n TM \n P-15 <span class=\"match\">Peptide</span> Enhanced Bone Graft. According to the applicant, PearlMatrix\n TM \n P-15 <span class=\"match\">Peptide</span> Enhanced Bone Graft is a composite bone graft material consisting of a synthetic <span class=\"match\">peptide</span>, found naturally occurring in human Type I collagen (P-15), adsorbed onto calcium phosphate particles, which are incorporated"}]}